Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada OKs SYN X' traumatic brain injury tests:

This article was originally published in Clinica

Executive Summary

SYN X Pharma has gained approval in Canada to sell serum-based test kits that measure what it claims are the first reliable biochemical markers of traumatic brain injury (TBI), such as Shaken Baby Syndrome. The Nexus Dx S-100 and Nexus Dx Neuron Specific Enolase (NSE) ELISA kits provide objective evidence of brain injury that will help physicians identify the Syndrome, allowing for child protection interventions, says the Toronto, Canada firm. SYN X is also developing a point-of-care TBI test.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel